Orally fast disintegrating solid preparation comprising aromatic component

Abstract

The present invention relates to an orally fast disintegrating solid preparation comprising an aromatic component as an active ingredient. The orally fast disintegrating solid preparation may be conveniently taken orally, and when taken, may be rapidly disintegrated in the oral cavity, thereby having the effect of enabling quick delivery of the aromatic component.

Description

Oral fast-disintegrating solid dosage forms containing fragrance ingredients

[0001] The present invention relates to an oral fast-disintegrating solid formulation containing a fragrance component, and more specifically, to an oral fast-disintegrating tablet or granule formulation containing a fragrance component as an active ingredient.

[0002] Since the onset of the COVID-19 pandemic in 2020, many virus patients have experienced a loss of smell. A loss of smell is a condition in which one cannot perceive odors, and it is caused by various factors such as abnormalities in olfactory cells and nerve conduction blockades.

[0003] The only way to reverse the loss of smell is through olfactory training. Olfactory training involves preparing scents known to continuously generate signaling stimuli within olfactory cells to reactivate the olfactory nervous system, and practicing smelling them consistently every day.

[0004] Fragrances consist of fragrance concentrates, which are concentrated volatile molecules with small molecular weights that evaporate easily, along with water, ethanol, solubilizers, and surfactants. These volatile molecules easily float in the air, and molecules with specific structures bind to olfactory receptor cells within the nasal epithelial tissue, generating signals that are transmitted to the brain to perceive odors.

[0005] However, patients exhibit low compliance due to the discomfort of placing their noses close to containers holding fragrances for olfactory training. Additionally, due to their high volatility, fragrance components generally leak out over time, resulting in poor stability in terms of storage.

[0006] Accordingly, the inventors, after diligent efforts, developed a granular and fast-disintegrating tablet composition that is easy to take and maintains a long-term aromatic component that helps restore the sense of smell without volatilizing during storage. The present invention was completed by confirming that the composition is easy to take and has excellent delivery as it possesses high flowability, compressibility, and a fast disintegration rate.

[0007] One objective of the present invention is to provide an oral fast-disintegrating solid formulation comprising a fragrance component as an active ingredient.

[0008] Another objective of the present invention is to provide an orally disintegrating tablet comprising a fragrance component as an active ingredient.

[0009] Another objective of the present invention is to provide a granular formulation comprising a fragrance component as an active ingredient.

[0010] The technical problems to be solved by the present invention are not limited to those mentioned above, and other unmentioned problems will be clearly understood by a person skilled in the art from the description below.

[0011] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention should not be considered limited by the specific descriptions provided below.

[0012] Furthermore, the terms used in this invention are for illustrative purposes only and should not be interpreted as intended to be limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this invention, terms such as “comprising” or “having” are intended to specify the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.

[0013] Furthermore, unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.

[0014] Furthermore, to prevent clutter caused by overlapping content, redundant details have been omitted below. In other words, the content of the invention is not limited solely to the following description, and should be interpreted in accordance with the overall context of the invention.

[0015]

[0016] The present invention relates to an oral solid dosage form containing an aromatic component as an active ingredient that can rapidly and safely provide a scent for the purpose of olfactory rehabilitation, olfactory training, or olfactory recovery. An oral solid dosage form (oral disintegrating tablet, granule formulation) optimized to rapidly disintegrate in the oral cavity upon ingestion so that the aromatic component can be rapidly delivered has been developed.

[0017]

[0018] Oral fast-disintegrating solid formulations containing aromatic ingredients

[0019] The present invention provides an oral solid dosage form comprising a fragrance component as an active ingredient.

[0020] In one aspect, a fragrance component comprising one or more selected from the group consisting of cinnamon scent, lemon scent, peppermint scent, rose scent and pine scent;

[0021] An adsorbent comprising one or more selected from the group consisting of silicon dioxide, magnesium aluminosilicate, calcium silicate, and powdered crystalline glucose; and

[0022] The present invention provides an oral fast-disintegrating solid formulation comprising one or more diluents selected from the group consisting of mannitol, sorbitol, xylitol, monohydrate lactose, microcrystalline cellulose, and corn starch.

[0023]

[0024] In the present invention, the term “aromatic component” may include aromatic compounds such as active aroma compounds, and said aromatic component may be a single aromatic component or a mixture of aromatic components. Additionally, said aromatic component may include a cinnamon scent, lemon scent, peppermint scent, rose scent, or pine scent capable of stimulating the sense of smell by binding to olfactory receptor cells in the epithelial tissue of the nose, or may be an essential oil, aroma oil, etc., containing an olfactory source capable of emitting these scents. Alternatively, it may be a natural extract, such as a cinnamon extract containing a cinnamon scent, a lemon extract containing a lemon scent, a peppermint extract containing a peppermint scent, a rose extract containing a rose scent, or a pine extract containing a pine scent.

[0025] In the present invention, with respect to 100 parts by weight of the solid formulation, the fragrance component may be 1 to 20 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, 1.8 parts by weight or more, or 2.0 parts by weight or more, and the upper limit may be 18 parts by weight or less, 16 parts by weight or less, 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 8 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, or 4.0 parts by weight or less. If the content of the fragrance component is less than 1 part by weight, the fragrance effect may be negligible, making it difficult to achieve the intended purpose of the product; if it exceeds 20 parts by weight, problems such as dizziness caused by the strong fragrance, reduced flowability, excessive hardness enhancement, and delayed disintegration time may occur, leading to deterioration in quality.

[0026] In the present invention, the adsorbent may preferably include one or more selected from silicon dioxide, magnesium aluminosilicate, and powdered crystalline glucose.

[0027] In the present invention, with respect to 100 parts by weight of the solid formulation, the adsorbent may be 1 to 20 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, 1.8 parts by weight or more, or 2.0 parts by weight or more, and the upper limit may be 18 parts by weight or less, 16 parts by weight or less, 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 8 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, or 4.0 parts by weight or less. If the content of the adsorbent is less than 1 part by weight, it may not sufficiently adsorb the fragrance component, resulting in a significant decrease in flowability and clumping; if it exceeds 20 parts by weight, it may cause a weakening of hardness, a dry mouth, and reduced patient preference, as well as a delayed disintegration time.

[0028] In addition, the above diluent may preferably include one or more selected from mannitol, sorbitol, and xylitol.

[0029] In the present invention, with respect to 100 parts by weight of the solid dosage form, the diluent may be 60 to 95 parts by weight, for example, the lower limit may be 62 parts by weight or more, 64 parts by weight or more, 66 parts by weight or more, 68 parts by weight or more, 70 parts by weight or more, 72 parts by weight or more, 74 parts by weight or more, 76 parts by weight or more, 78 parts by weight or more, 80 parts by weight or more, 82 parts by weight or more, or 84 parts by weight or more, and the upper limit may be 94 parts by weight or less, 93 parts by weight or less, 92 parts by weight or less, 91 parts by weight or less, or 90 parts by weight or less. If the content of the diluent is less than 60 parts by weight, problems such as reduced flowability and reduced spreadability and disintegration in the oral cavity may occur, and if it exceeds 95 parts by weight, problems such as weakened tablet hardness and inconvenience of taking medication due to increased dosage may occur.

[0030] In the present invention, the solid dosage form may further include one or more additives selected from disintegrants, lubricants, binders, and volatilization inhibitors. The additives may be optionally included depending on the formulation of the solid dosage form.

[0031] In the present invention, the term “disintegrant” refers to a substance added for the purpose of promoting the disintegration of tablets, capsules, granules, etc., in digestive fluid. Specifically, the disintegrant may include one or more selected from Kollidon CL, Kollidon CL-F, low-substituted hydroxypropylcellulose (L-HPC), croscarmellose, sodium starch glycolate, and polyvinylpyrrolidone (PVP), and preferably may include one or more of Kollidon CL and Kollidon CL-F.

[0032] In the present invention, with respect to 100 parts by weight of the solid dosage form, the disintegrant may be 2 to 20 parts by weight, for example, the lower limit may be 2.2 parts by weight or more, 2.4 parts by weight or more, 2.6 parts by weight or more, 2.8 parts by weight or more, 3.0 parts by weight or more, 3.2 parts by weight or more, 3.4 parts by weight or more, 3.6 parts by weight or more, 3.8 parts by weight or more, 4.0 parts by weight or more, 4.2 parts by weight or more, 4.4 parts by weight or more, 4.6 parts by weight or more, or 4.8 parts by weight or more, and the upper limit may be 18 parts by weight or less, 16 parts by weight or less, 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 9.5 parts by weight or less, 9.0 parts by weight or less, 8.5 parts by weight or less, 8.0 parts by weight or less, 7.8 parts by weight or less, 7.6 parts by weight or less, 7.4 parts by weight The amount may be 7.2 parts by weight or less, 7.0 parts by weight or less, 6.8 parts by weight or less, 6.6 parts by weight or less, 6.4 parts by weight or less, 6.2 parts by weight or less, 6.0 parts by weight or less, or 5.5 parts by weight or less. If the content of the disintegrant is less than 2 parts by weight, the disintegration rate may be delayed, which may cause problems such as delayed release of the active ingredient / effective ingredient; if it exceeds 20 parts by weight, flowability and binding strength may be weakened, and quality may be degraded.

[0033] In the present invention, the term “lubricant” refers to an additive used to provide fluidity to granules when making tablets and to make it easier for the tablets to come out of the mold. Specifically, the lubricant may include one or more selected from the group consisting of magnesium stearate, sodium stearyl fumarate, talc, and polyethylene glycol, and preferably may be magnesium stearate.

[0034] In the present invention, the amount of a lubricant may be 0.5 to 4 parts by weight with respect to 100 parts by weight of the solid formulation, for example, the lower limit may be 0.6 parts by weight or more, 0.7 parts by weight or more, 0.8 parts by weight or more, 0.9 parts by weight or more, or 0.95 parts by weight or more, and the upper limit may be 3.8 parts by weight or less, 3.6 parts by weight or less, 3.4 parts by weight or less, 3.2 parts by weight or less, 3.0 parts by weight or less, 2.8 parts by weight or less, 2.6 parts by weight or less, 2.4 parts by weight or less, or 2.2 parts by weight or less. If the content of the lubricant is less than 0.5 parts by weight, problems such as reduced flowability and decreased efficiency of the manufacturing process may occur, and if it exceeds 4 parts by weight, problems such as static electricity generation, weakened bonding strength, and reduced uniformity of components may occur.

[0035] In the present invention, the term “binder” refers to a substance that helps powdered components of a drug clump together to form granules, and assists in securing appropriate compressibility and mechanical strength in the granules themselves and during the tableting process. Specifically, the binder may include one or more selected from the group consisting of hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), pregelatinized starch, Kollidone 30, and Kollidone VA 64, and preferably may include one or more of hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC).

[0036] In the present invention, with respect to 100 parts by weight of the solid formulation, the binder may be in an amount of 2 to 16 parts by weight, for example, the lower limit may be 2.2 parts by weight or more, 2.4 parts by weight or more, 2.6 parts by weight or more, 2.8 parts by weight or more, 3.0 parts by weight or more, 3.2 parts by weight or more, 3.4 parts by weight or more, 3.6 parts by weight or more, or 3.8 parts by weight or more, and the upper limit may be 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 8 parts by weight or less, 7.8 parts by weight or less, 7.6 parts by weight or less, 7.4 parts by weight or less, 7.2 parts by weight or less, 7.0 parts by weight or less, 6.8 parts by weight or less, 6.6 parts by weight or less, 6.4 parts by weight or less, 6.2 parts by weight or less, 6.0 parts by weight or less, 5.8 parts by weight or less, 5.6 parts by weight or less, 5.4 parts by weight or less, It may be 5.2 parts by weight or less, 5.0 parts by weight or less, or 4.5 parts by weight or less. If the content of the binder is less than 2 parts by weight, the hardness is weakened and flowability is reduced, which may cause problems with the physical stability of the tablet, and if it exceeds 16 parts by weight, the hardness is excessively strengthened and the disintegration time is delayed, which may cause problems with reduced performance.

[0037] In addition, the term “volatile inhibitor” in the present invention includes edible oil-based substances used for the purpose of inhibiting the volatilization of aromatic components that tend to volatilize over time. Specifically, it may include one or more selected from the group consisting of olive oil, soybean oil, canola oil, grapeseed oil, and sunflower oil.

[0038] In the present invention, with respect to 100 parts by weight of the solid formulation, the volatile inhibitor may be 1 to 12 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, or 1.8 parts by weight or more, and the upper limit may be 10 parts by weight or less, 9.5 parts by weight or less, 9 parts by weight or less, 8.5 parts by weight or less, 8 parts by weight or less, 7.5 parts by weight or less, 7 parts by weight or less, 6.5 parts by weight or less, 6 parts by weight or less, 5.5 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, 4.0 parts by weight or less, 3.8 parts by weight or less, 3.6 parts by weight or less, 3.4 parts by weight or less, 3.2 parts by weight or less, 3.0 parts by weight or less, 2.8 parts by weight or less, or It may be 2.6 parts by weight or less. If the content of the volatilization inhibitor is less than 1 part by weight, a problem may occur in which the volatilization inhibitory effect of the fragrance component is reduced, and if it exceeds 12 parts by weight, the flowability of the granules is significantly reduced, the strength of the granules and tablets is reduced, and the scent of the volatilization inhibitor becomes excessively strong, which may cause a problem in which the scent of the fragrance component is weakened.

[0039] In the present invention, the solid formulation may be a granule, tablet, capsule, or dry syrup, and preferably may be a tablet or granule.

[0040] The above solid dosage form may have a hardness of 3 to 7 kP, preferably in the range of 4 to 6 kP, and more preferably in the range of 4.5 to 5.5 kP. If the hardness is less than 3 kP, the tablet breaks easily, which reduces portability and ease of handling, and if it exceeds 7 kP, the disintegration time is excessively delayed, which delays the release of the active ingredient / active ingredient.

[0041] In this invention, the term “hardness” refers to the magnitude of resistance to deformation of an object when it is pressed by another object; as the simplest method for determining the mechanical properties of a material, it plays an important role in material testing. Methods for measuring hardness include Brinell hardness, Rockwell hardness, and Shore hardness; however, there are no particular limitations on the method for measuring the hardness of the orally disintegrating tablets manufactured in this invention, and hardness can generally be measured using methods widely known in the field of this invention.

[0042] The above solid dosage form may have an oral disintegration time of 30 seconds or less, preferably 25 seconds or less, and more preferably 20 seconds or less. If the oral disintegration time exceeds 30 seconds, it is not suitable as an oral rapid disintegrating tablet.

[0043] In the present invention, the term “disintegration time” refers to the phenomenon in which a solid formulation is lost in a test solution or dispersed to a particle state or lower than that specified in the Korean Pharmacopoeia, and does not mean the complete dissolution of the active ingredient. The disintegration time can be measured using known methods generally used to measure the disintegration time of orally disintegrating tablets.

[0044] The solid dosage form of the present invention is an orally disintegrating tablet having a hardness within an appropriate range and a short disintegration time of within 30 seconds.

[0045] In addition, the solid formulation of the present invention is a granular formulation with excellent flowability, making it convenient to take.

[0046]

[0047] Oral disintegrating tablets containing aromatic ingredients

[0048] The present invention provides an oral disintegrating tablet containing a fragrance component as an active ingredient.

[0049] In another aspect, the present invention comprises a fragrance component comprising one or more selected from the group consisting of cinnamon scent, lemon scent, peppermint scent, rose scent and pine scent;

[0050] An adsorbent comprising one or more selected from the group consisting of silicon dioxide, magnesium aluminosilicate, calcium silicate, and powdered crystalline glucose;

[0051] A diluent comprising one or more selected from the group consisting of mannitol, sorbitol, xylitol, monohydrate lactose, microcrystalline cellulose, and corn starch; and

[0052] The present invention provides an orally disintegrating tablet comprising one or more disintegrating agents selected from the group consisting of kollidone CL, kollidone CL-F, low-substituted hydroxypropylcellulose (L-HPC), croscarmellose, sodium starch glycolate, and polyvinylpyrrolidone (PVP).

[0053]

[0054] In the present invention, the term “oral disintegrating tablet” refers to a product that facilitates the administration of a drug by promoting disintegration through saliva in the oral cavity, and is used interchangeably with oral disintegrating agents, oral disintegrating tablets, rapid disintegrating tablets, or rapid disintegrating agents.

[0055] The explanation regarding the “directional component” above is as previously stated.

[0056] In the present invention, with respect to 100 parts by weight of the oral disintegrating tablet, the aromatic component may be 1 to 20 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, 1.8 parts by weight or more, or 2.0 parts by weight or more, and the upper limit may be 18 parts by weight or less, 16 parts by weight or less, 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 8 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, or 4.0 parts by weight or less. If the content of the fragrance component is less than 1 part by weight, the fragrance effect may be negligible, making it difficult to achieve the intended purpose of the product; if it exceeds 20 parts by weight, problems such as dizziness caused by the strong fragrance, reduced flowability, excessive hardness enhancement, and delayed disintegration time may occur, leading to deterioration in quality.

[0057] In the present invention, the adsorbent may preferably include one or more selected from silicon dioxide, magnesium aluminosilicate, and powdered crystalline glucose.

[0058] In the present invention, with respect to 100 parts by weight of the oral disintegrating tablet, the adsorbent may be 1 to 20 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, 1.8 parts by weight or more, or 2.0 parts by weight or more, and the upper limit may be 18 parts by weight or less, 16 parts by weight or less, 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 8 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, or 4.0 parts by weight or less. If the content of the adsorbent is less than 1 part by weight, it may not sufficiently adsorb the fragrance component, resulting in a significant decrease in flowability and clumping; if it exceeds 20 parts by weight, it may cause a weakening of hardness, a dry mouth, and reduced patient preference, as well as a delayed disintegration time.

[0059] In addition, the diluent may preferably include mannitol, and more preferably D-mannitol.

[0060] In the present invention, with respect to 100 parts by weight of the oral disintegrating tablet, the diluent may be 60 to 95 parts by weight, for example, the lower limit may be 62 parts by weight or more, 64 parts by weight or more, 66 parts by weight or more, 68 parts by weight or more, 70 parts by weight or more, 72 parts by weight or more, 74 parts by weight or more, 76 parts by weight or more, 78 parts by weight or more, 80 parts by weight or more, 82 parts by weight or more, or 84 parts by weight or more, and the upper limit may be 94 parts by weight or less, 93 parts by weight or less, 92 parts by weight or less, 91 parts by weight or less, or 90 parts by weight or less. If the diluent content is less than 60 parts by weight, problems such as reduced flowability and reduced spreadability and disintegration in the oral cavity may occur, and if it exceeds 95 parts by weight, problems such as weakened tablet hardness and inconvenience of taking medication due to increased dosage may occur.

[0061] The above disintegrant may preferably be colidone CL or colidone CL-F, and more preferably colidone CL-F.

[0062] In the present invention, with respect to 100 parts by weight of the oral disintegrating tablet, the disintegrant may be 2 to 20 parts by weight, for example, the lower limit may be 2.2 parts by weight or more, 2.4 parts by weight or more, 2.6 parts by weight or more, 2.8 parts by weight or more, 3.0 parts by weight or more, 3.2 parts by weight or more, 3.4 parts by weight or more, 3.6 parts by weight or more, 3.8 parts by weight or more, 4.0 parts by weight or more, 4.2 parts by weight or more, 4.4 parts by weight or more, 4.6 parts by weight or more, or 4.8 parts by weight or more, and the upper limit may be 18 parts by weight or less, 16 parts by weight or less, 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 9.5 parts by weight or less, 9.0 parts by weight or less, 8.5 parts by weight or less, 8.0 parts by weight or less, 7.8 parts by weight or less, 7.6 parts by weight or less, 7.4 It may be less than or equal to 7.2 parts by weight, less than or equal to 7.0 parts by weight, less than or equal to 6.8 parts by weight, less than or equal to 6.6 parts by weight, less than or equal to 6.4 parts by weight, less than or equal to 6.2 parts by weight, less than or equal to 6.0 parts by weight, or less than or equal to 5.5 parts by weight. If the content of the disintegrant is less than 2 parts by weight, the disintegration rate may be delayed, which may cause problems such as delayed release of the active ingredient / effective ingredient, and if it exceeds 20 parts by weight, flowability and binding strength may be weakened, and quality may be degraded.

[0063] In the present invention, the oral disintegrating tablet may further include one or more additives among a lubricant and a volatilization inhibitor.

[0064] The above lubricant may include one or more selected from the group consisting of magnesium stearate, sodium stearyl fumarate, talc, and polyethylene glycol, and preferably may be magnesium stearate.

[0065] In the present invention, with respect to 100 parts by weight of the oral disintegrating tablet, the amount of lubricant may be 0.5 to 4 parts by weight, for example, the lower limit may be 0.6 parts by weight or more, 0.7 parts by weight or more, 0.8 parts by weight or more, 0.9 parts by weight or more, or 0.95 parts by weight or more, and the upper limit may be 3.8 parts by weight or less, 3.6 parts by weight or less, 3.4 parts by weight or less, 3.2 parts by weight or less, 3.0 parts by weight or less, 2.8 parts by weight or less, 2.6 parts by weight or less, 2.4 parts by weight or less, or 2.2 parts by weight or less. If the content of the lubricant is less than 0.5 parts by weight, problems such as reduced flowability and decreased efficiency of the manufacturing process may occur, and if it exceeds 4 parts by weight, problems such as static electricity generation, weakened bonding strength, and reduced uniformity of components may occur.

[0066] The above-mentioned volatilization inhibitor may include one or more selected from the group consisting of olive oil, soybean oil, canola oil, grapeseed oil, and sunflower oil, and preferably may include olive oil.

[0067] In the present invention, with respect to 100 parts by weight of the oral rapid disintegrating tablet, the volatile inhibitor may be 1 to 12 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, or 1.8 parts by weight or more, and the upper limit may be 10 parts by weight or less, 9.5 parts by weight or less, 9 parts by weight or less, 8.5 parts by weight or less, 8 parts by weight or less, 7.5 parts by weight or less, 7 parts by weight or less, 6.5 parts by weight or less, 6 parts by weight or less, 5.5 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, 4.0 parts by weight or less, 3.8 parts by weight or less, 3.6 parts by weight or less, 3.4 parts by weight or less, 3.2 parts by weight or less, 3.0 parts by weight or less, 2.8 parts by weight or less, or It may be 2.6 parts by weight or less. If the content of the volatilization inhibitor is less than 1 part by weight, the volatilization inhibitor effect may be negligible, and the volatilization inhibitor effect of the fragrance component may be reduced. If it exceeds 12 parts by weight, the flowability of the granules may be significantly reduced, the strength of the granules and tablets may be reduced, and the scent of the volatilization inhibitor may become excessively strong, causing the scent of the fragrance component to be weakened.

[0068] In the present invention, the oral disintegrating tablet may have a hardness of 3 to 7 kP, preferably in the range of 4 to 6 kP, and more preferably in the range of 4.5 to 5.5 kP. If the hardness is less than 3 kP, the tablet breaks easily, which reduces portability and ease of handling, and if it exceeds 7 kP, the disintegration time is excessively delayed, which delays the release of the active ingredient / active ingredient.

[0069] In the present invention, the oral rapid disintegrating tablet may have an oral disintegration time of 30 seconds or less, preferably 25 seconds or less, and more preferably 20 seconds or less. If the oral disintegration time exceeds 30 seconds, it is not suitable as an oral rapid disintegrating tablet.

[0070] In one embodiment, an oral disintegrating tablet is provided comprising: a fragrance component comprising one or more selected from the group consisting of cinnamon, lemon, peppermint, rose, and pine scents; an adsorbent comprising one or more selected from the group consisting of silicon dioxide, magnesium aluminosilicate, and powdered crystalline glucose; a diluent comprising mannitol; a disintegrant comprising Kollidon CL-F; and a lubricant comprising magnesium stearate.

[0071] In addition, the oral disintegrating tablet may comprise, with respect to 100 parts by weight of the oral disintegrating tablet, 2 to 10 parts by weight of a fragrance component; 2 to 5 parts by weight of an adsorbent; 80 to 90 parts by weight of a diluent; 2 to 10 parts by weight of a disintegrant; and 0.5 to 2 parts by weight of a lubricant.

[0072] In addition, the above-mentioned oral disintegrating tablet may further include a volatile inhibitor. Depending on the type of the active ingredient, the volatile inhibitor may be selectively used when the volatile ingredient is highly volatile, and the description of the volatile inhibitor is as previously described.

[0073] The oral disintegrating tablet of the present invention has an appropriate range of hardness and a short disintegration time of within 30 seconds as an oral disintegrating tablet.

[0074]

[0075] Oral fast-disintegrating granular preparations containing aromatic ingredients

[0076] The present invention provides a granule formulation comprising a fragrance component as an active ingredient.

[0077] In one aspect, a fragrance component comprising one or more selected from the group consisting of cinnamon scent, lemon scent, peppermint scent, rose scent and pine scent;

[0078] An adsorbent comprising one or more selected from the group consisting of silicon dioxide, magnesium aluminosilicate, calcium silicate, and powdered crystalline glucose;

[0079] A diluent comprising one or more selected from the group consisting of mannitol, sorbitol, xylitol, monohydrate lactose, microcrystalline cellulose, and corn starch; and

[0080] A granule formulation is provided comprising a binder comprising one or more selected from the group consisting of hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), pregelatinized starch, Kollidone 30, and Kollidone VA 64.

[0081]

[0082] In the present invention, the term “granule preparation” refers to a method of facilitating the administration of a drug by promoting disintegration by saliva in the oral cavity, and is used interchangeably with granule compositions, granule preparations, etc.

[0083] The explanation regarding the “directional component” above is as previously stated.

[0084] In the present invention, with respect to 100 parts by weight of the granule formulation, the fragrance component may be 1 to 12 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, 1.8 parts by weight or more, or 2.0 parts by weight or more, and the upper limit may be 11 parts by weight or less, 10 parts by weight or less, 9 parts by weight or less, 8 parts by weight or less, 7 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, or 4.0 parts by weight or less. If the content of the fragrance component is less than 1 part by weight, the fragrance effect may be negligible, making it difficult to achieve the purpose of the product; if it exceeds 12 parts by weight, problems such as dizziness caused by the strong fragrance, reduced flowability, excessive hardness enhancement, and delayed disintegration time may occur, leading to deterioration of quality.

[0085] The above adsorbent may preferably include silicon dioxide.

[0086] In the present invention, with respect to 100 parts by weight of the granule formulation, the adsorbent may be 1 to 12 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, 1.8 parts by weight or more, or 2.0 parts by weight or more, and the upper limit may be 11 parts by weight or less, 10 parts by weight or less, 9 parts by weight or less, 8 parts by weight or less, 7 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, or 4.0 parts by weight or less, 3.8 parts by weight or less, 3.6 parts by weight or less, 3.2 parts by weight or less, 3.0 parts by weight or less, 2.8 parts by weight or less, or 2.6 parts by weight or less. If the content of the adsorbent is less than 1 part by weight, it may not sufficiently adsorb the fragrance component, resulting in a significant decrease in flowability and clumping; if it exceeds 12 parts by weight, it may cause a weakening of hardness, a dry mouth, and reduced patient preference, as well as a delayed disintegration time.

[0087] In addition, the above diluent may preferably include one or more selected from mannitol, sorbitol, and xylitol, and more preferably may include mannitol, sorbitol, and xylitol.

[0088] In the present invention, with respect to 100 parts by weight of the granule formulation, the diluent may be 60 to 95 parts by weight, for example, the lower limit may be 62 parts by weight or more, 64 parts by weight or more, 66 parts by weight or more, 68 parts by weight or more, 70 parts by weight or more, 72 parts by weight or more, 74 parts by weight or more, 76 parts by weight or more, 78 parts by weight or more, 80 parts by weight or more, 82 parts by weight or more, or 84 parts by weight or more, and the upper limit may be 94 parts by weight or less, 93 parts by weight or less, 92 parts by weight or less, 91 parts by weight or less, or 90 parts by weight or less. If the content of the diluent is less than 60 parts by weight, problems such as reduced flowability and reduced spreadability and disintegration in the oral cavity may occur, and if it exceeds 95 parts by weight, problems such as weakened tablet hardness and inconvenience of taking medication due to increased dosage may occur.

[0089] In addition, the binder may preferably be hydroxypropyl cellulose (HPC) or hydroxypropyl methylcellulose (HPMC), and more preferably hydroxypropyl cellulose (HPC).

[0090] In the present invention, with respect to 100 parts by weight of the granule formulation, the binder may be in an amount of 2 to 16 parts by weight, for example, the lower limit may be 2.2 parts by weight or more, 2.4 parts by weight or more, 2.6 parts by weight or more, 2.8 parts by weight or more, 3.0 parts by weight or more, 3.2 parts by weight or more, 3.4 parts by weight or more, 3.6 parts by weight or more, or 3.8 parts by weight or more, and the upper limit may be 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 8 parts by weight or less, 7.8 parts by weight or less, 7.6 parts by weight or less, 7.4 parts by weight or less, 7.2 parts by weight or less, 7.0 parts by weight or less, 6.8 parts by weight or less, 6.6 parts by weight or less, 6.4 parts by weight or less, 6.2 parts by weight or less, 6.0 parts by weight or less, 5.8 parts by weight or less, 5.6 parts by weight or less, 5.4 parts by weight or less. It may be 5.2 parts by weight or less, 5.0 parts by weight or less, or 4.5 parts by weight or less. If the content of the binder is less than 2 parts by weight, the hardness is weakened and flowability is reduced, which may cause problems with the physical stability of the tablet, and if it exceeds 16 parts by weight, the hardness is excessively strengthened and the disintegration time is delayed, which may cause problems with reduced performance.

[0091] In the present invention, the granule formulation may further include one or more additives among a lubricant and a volatilization inhibitor.

[0092] The above lubricant may include one or more selected from the group consisting of magnesium stearate, sodium stearyl fumarate, talc, and polyethylene glycol, and preferably may be magnesium stearate.

[0093] In the present invention, the amount of a lubricant may be 1 to 4 parts by weight per 100 parts by weight of the granule formulation, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, or 1.8 parts by weight or more, and the upper limit may be 3.8 parts by weight or less, 3.6 parts by weight or less, 3.4 parts by weight or less, 3.2 parts by weight or less, 3.0 parts by weight or less, 2.8 parts by weight or less, 2.6 parts by weight or less, 2.4 parts by weight or less, or 2.2 parts by weight or less. If the content of the lubricant is less than 1 part by weight, problems such as reduced flowability and decreased efficiency of the manufacturing process may occur, and if it exceeds 4 parts by weight, problems such as static electricity generation, weakened binding force, and reduced uniformity of ingredients may occur.

[0094] The above-mentioned volatilization inhibitor may include one or more selected from the group consisting of olive oil, soybean oil, canola oil, grapeseed oil, and sunflower oil, and preferably may include olive oil.

[0095] In addition, with respect to 100 parts by weight of the granule formulation, the volatile inhibitor may be 1 to 12 parts by weight, for example, the lower limit may be 1.2 parts by weight or more, 1.4 parts by weight or more, 1.6 parts by weight or more, or 1.8 parts by weight or more, and the upper limit may be 11 parts by weight or less, 10 parts by weight or less, 9 parts by weight or less, 8 parts by weight or less, 7 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less, 4.8 parts by weight or less, 4.6 parts by weight or less, 4.4 parts by weight or less, 4.2 parts by weight or less, or 4.0 parts by weight or less, 3.8 parts by weight or less, 3.6 parts by weight or less, 3.4 parts by weight or less, 3.2 parts by weight or less, 3.0 parts by weight or less, 2.8 parts by weight or less, 2.6 parts by weight or less, 2.4 parts by weight or less, or 2.2 parts by weight or less. If the content of the volatile inhibitor is less than 1 part by weight, the volatile inhibitor effect may be negligible, which may result in a decrease in the volatile inhibitor effect of the fragrance component; if it exceeds 12 parts by weight, the flowability of the granules may be significantly reduced, the strength of the granules and tablets may be reduced, and the scent of the volatile inhibitor may become excessively strong, which may result in a weakening of the fragrance component.

[0096] In the present invention, the granule formulation may have a particle size in the range of 10 to 500 μm, preferably 15 to 480 μm, and more preferably 20 to 450 μm.

[0097] The granule formulation of the present invention may have a Carr's index range of 20 or less, preferably 15 or less.

[0098] In one embodiment, the granule formulation may comprise: a fragrance component comprising one or more selected from the group consisting of cinnamon scent, lemon scent, peppermint scent, rose scent, and pine scent; an adsorbent comprising silicon dioxide; a diluent comprising one or more selected from the group consisting of mannitol, sorbitol, and xylitol; a binder comprising hydroxypropyl cellulose (HPC); and a lubricant comprising magnesium stearate; and may further comprise a volatilization inhibitor comprising one or more selected from the group consisting of olive oil, soybean oil, canola oil, grapeseed oil, and sunflower oil.

[0099] In addition, the granule formulation may comprise, with respect to 100 parts by weight of the granule formulation, 1 to 8 parts by weight of a fragrance component; 1 to 8 parts by weight of an adsorbent; 70 to 92 parts by weight of a diluent; 2 to 10 parts by weight of a binder; 1 to 4 parts by weight of a lubricant, and may additionally comprise 1 to 8 parts by weight of a volatilization inhibitor.

[0100] The granule formulation of the present invention has excellent flowability, so it is easy to take.

[0101] The oral disintegrating solid formulation containing the aromatic component of the present invention can be conveniently taken orally and has the effect of rapidly disintegrating in the oral cavity upon taking, thereby rapidly delivering the aromatic component.

[0102] The above-mentioned solid formulation contains aromatic components and can be used for the purpose of olfactory rehabilitation, training, and recovery.

[0103] The present invention will be explained in more detail below through examples. However, these examples are intended to illustrate the invention and the scope of the invention is not limited to these examples.

[0104] Example 1. Preparation of an orally disintegrating tablet containing a fragrance component

[0105] Oral disintegrating tablets were manufactured with the ingredient composition and content as shown in Table 2 below.

[0106] Specifically, the adsorbent obtained by adsorbing the liquid fragrance component and the adsorbent of Table 1 below in a 1:1 ratio was placed in a mortar with other additives excluding the lubricant and mixed using a pestle to obtain a mixture (1). The mixture (1) of each fragrance component was homogenized using a 300 μm sieve to obtain a mixture (2). The mixture (2) obtained through the sifting process was homogenized with the lubricant into a bag to obtain a mixture (3). Subsequently, the mixture (3) was compressed at 15 kN in a rotary tablet press to produce a fast-disintegrating tablet.

[0107] Fragrance Ingredient (Product Name) Grade Manufacturer / Supplier Cinnamon Scent (EM-16B103) Food Grade ES Food Ingredient Lemon Scent (EM-16B085) Food Grade ES Food Ingredient Mint Scent (FM110214) Food Grade ES Food Ingredient Mint Scent Powder (PM120403) Food Grade ES Food Ingredient Pine Scent (EM-18B052A) Food Grade ES Food Ingredient Pine Scent Powder 1 (PP130628) Food Grade ES Food Ingredient Rose Scent (EM-17P020) Food Grade ES Food Ingredient

[0108]

[0109]

[0110] Example 2. Preparation of a granular formulation containing a fragrance component (pre-mixing)

[0111] A granule formulation was prepared with the ingredient composition and content as shown in Table 3 below.

[0112] Specifically, an adsorbent was first prepared by adsorbing a liquid fragrance component and an adsorbent in a 1:1 weight ratio. The adsorbent, along with other additives (diluent, binder), was placed in a mortar and pestle and homogeneously mixed using a pestle. Subsequently, ethanol was evenly added dropwise to the mixture in the mortar at a rate of 10% of the total weight, and the mixture was granulated again using a pestle. To remove the ethanol from the granules, the mixture was stored in a 40°C oven for 30 minutes to 1 hour to obtain granules from which the binder had been removed. Afterward, to obtain a homogeneous particle size, the dried granules were taken and sieved through a 500 μm mesh to obtain granulated granules. The granulated granules and a lubricant (magnesium stearate) were placed in a bag in the prescribed amount and mixed to obtain a homogeneous final granular formulation.

[0113]

[0114]

[0115] Example 3. Preparation of a granular formulation containing a fragrance component (post-mixing)

[0116] A granule formulation was prepared with the ingredient composition and content as shown in Table 4 below.

[0117] Specifically, an adsorbent was first prepared by adsorbing a liquid fragrance component and an adsorbent. The adsorbent and other additives, excluding the lubricant, were placed in a mortar and pestle and mixed homogeneously using a pestle. Subsequently, ethanol was evenly added dropwise to the mixture in the mortar at an amount of 10% of the total weight, and the mixture was granulated again using a pestle. To remove the ethanol from the granules, the mixture was stored in a 40°C oven for 30 minutes to 1 hour to obtain granules from which the binding solution had been removed. Afterward, to obtain a homogeneous particle size, the dried granules were taken and sieved through a 500 μm mesh to obtain granulated granules. The granulated granules, the lubricant (magnesium stearate), and the fragrance component adsorbent were placed in a bag in the prescribed amount and mixed to obtain a homogeneous granular formulation.

[0118]

[0119]

[0120] Example 4. Screening of volatilization inhibitor components for the preparation of granule formulations containing volatilization inhibitors

[0121] When granules containing fragrance ingredients are packaged in pouches, the fragrance tends to volatilize over time. Therefore, to suppress volatilization, an edible oil was additionally added as a volatilization inhibitor to prepare a granule formulation. The composition and content of the granule formulation are as shown in Table 5 below.

[0122] An adsorbent was prepared by mixing a volatilization inhibitor, a fragrance component, and an adsorbent. A diluent and a binder were placed in a mortar and pestle and mixed homogeneously using a pestle. Then, ethanol was evenly added dropwise to the mixture in the mortar at a rate of 10% of the total weight, and the mixture was granulated again using a pestle. To remove ethanol from the granules, the mixture was stored in a 40°C oven for 30 minutes to 1 hour to obtain granules from which the binder had been removed. Subsequently, to obtain a homogeneous particle size, the dried granules were taken and sieved through a 500 μm mesh to obtain granulated granules. The adsorbent and the granules were mixed and packaged in pouches. The glass pouches containing the mixture were stored in a 50°C oven for 7 days, and the content of the fragrance component and Carr's index were analyzed before and after storage. The analysis results are shown in Table 5 below.

[0123]

[0124] As can be seen in Table 5, the granule formulations of Examples 4-1 to 4-5 containing volatilization inhibitors were found to have excellent volatilization inhibition effects and flowability of over 70%. Therefore, it was confirmed that five types of olive oil, soybean oil, canola oil, grapeseed oil, and sunflower oil can be used as volatilization inhibitors for the manufacture of granule formulations.

[0125]

[0126] Example 5. Preparation of a granule formulation additionally containing a volatilization inhibitor component

[0127] A granule formulation was prepared with the ingredient composition and content as shown in Table 6 below.

[0128] Specifically, first, an adsorbent was prepared by adsorbing the liquid fragrance component and the adsorbent in the weight ratio shown in Table 6, and then a fragrance adsorbent was prepared by additionally adsorbing the said adsorbent and a volatility inhibitor in a weight ratio of 2:1. The diluent and binder were placed in a mortar and pestle and mixed homogeneously using a pestle. Ethanol was evenly added dropwise to the mixture in the mortar at an amount of 10% of the total weight, and then granulated again using a pestle. To remove the ethanol from the granules, the mixture was stored in a 40°C oven for 30 minutes to 1 hour to obtain granules from which the binder had been removed. Subsequently, to obtain a homogeneous particle size, the dried granules were taken and sieved through a 500 μm mesh to obtain granulated granules. The granulated granules, lubricant (magnesium stearate), and fragrance adsorbent were placed in a bag in the prescribed amount and mixed to obtain a homogeneous granular formulation.

[0129]

[0130] Example 6. Analysis of the characteristics of an orally disintegrating tablet containing a fragrance component

[0131] To evaluate the formulation suitability of the oral disintegrating tablet prepared according to Example 1, hardness, disintegration time, and scent were analyzed.

[0132] First, the oral rapid disintegrating tablet prepared according to Example 1 was evaluated as suitable when it exhibited a hardness of 3-7 kP using a hardness meter. Additionally, it was evaluated as suitable as a rapid disintegrating tablet when it disintegrated within 30 seconds through a disintegration test using a disintegration tester with 900 mL of distilled water. The analysis results are shown in Table 7 below.

[0133] Analysis Item Example 1-1 Example 1-2 Example 1-3 Example 1-4 Example 1-5 Example 1-6 Example 1-7 Example 1-8 Hardness 4.6 5 6.4 7 4.7 3 5.1 4 5.2 4 5.8 7 4.8 4 6.3 1 Disintegration Time (seconds) 1 4 2 2 1 6 1 1 1 5 2 8 1 4 2 1

[0134] As shown in Table 7 above, the rapid disintegrating tablets of Examples 1-1 to 1-8 were found to have a disintegration time of less than 30 seconds as a result of the disintegration test, and had an appropriate hardness of within 3 to 7 kP. Through this, it was confirmed that the tablet prepared according to Example 1 is suitable as a rapid disintegrating tablet.

[0135]

[0136] Example 7. Evaluation of flowability of granule formulation containing fragrance components

[0137] Carr's index was evaluated to assess the flowability of the granule formulation prepared according to Example 3. Specifically, 10 g of the granule formulation prepared according to Example 3 was placed in a cylinder, the initial height was recorded, and the cylinder was struck 100 times toward the floor to record the change in height. This process was repeated 100 more times, and the final height was set when the change in height was within 5% of the previous record. The volume immediately after dropping and the compressed volume were calculated using the cylinder area, the height immediately after dropping, and the final height. Subsequently, Carr's index was calculated using the formula (Volume immediately after dropping - Compressed volume) / Volume immediately after dropping x 100. It was determined to be suitable when the calculated Carr's index was within 20. The analysis results are shown in Table 8 below.

[0138] Evaluation Items Example 3-1 Example 3-3 Example 3-4 Example 3-5 Example 3-6 Example 3-7 Example 3-8 Carr's index 7.86.4 19.87.6 17.25.2 18.6

[0139] As shown in Table 8, it was confirmed that the granule formulations of Examples 3-1, 3-3 to 3-8 have excellent flowability with a Carr's index of 20 or less.

[0140]

[0141] Example 8. Evaluation of flowability of a granule formulation containing a volatilization inhibitor

[0142] Carr's index was evaluated to assess the flowability of the granule formulation additionally containing the volatilization inhibitor prepared according to Example 5. Specifically, 10 g of the granule formulation prepared according to Example 5 was placed in a cylinder, the initial height was recorded, and the cylinder was struck 100 times toward the floor to record the change in height. This process was repeated 100 more times, and the final height was set when the change in height was within 5% of the previous record. The volume immediately after dropping and the compressed volume were calculated using the cylinder area, the height immediately after dropping, and the final height. Subsequently, Carr's index was calculated using the formula (Volume immediately after dropping - Compressed volume) / Volume immediately after dropping x 100. It was determined to be suitable when the calculated Carr's index was within 20. The analysis results are shown in Table 9 below.

[0143] Analysis Item Example 5-1 Example 5-2 Example 5-3 Example 5-4 Example 5-5 Example 5-6 Example 5-7 Example 5-8 Carr's index 11.5 18.6 13.4 18.7 13.7 15.7 12.1 16.9

[0144] As can be seen in Table 9, the granule formulations prepared according to Examples 5-1 to 5-8 showed a Carr's index of 20 or less, indicating excellent flowability.

Claims

1. A fragrance component comprising one or more selected from the group consisting of cinnamon scent, lemon scent, peppermint scent, rose scent and pine scent; An adsorbent comprising one or more selected from the group consisting of silicon dioxide, magnesium aluminosilicate, calcium silicate, and powdered crystalline glucose; and An oral fast-disintegrating solid dosage form comprising one or more diluents selected from the group consisting of mannitol, sorbitol, xylitol, monohydrate lactose, microcrystalline cellulose, and corn starch.

2. The oral fast-disintegrating solid formulation according to claim 1, wherein the solid formulation further comprises one or more additives selected from a disintegrant, a lubricant, a binder, and a volatilization inhibitor.

3. An oral fast-disintegrating solid dosage form according to paragraph 2, wherein the disintegrating agent comprises one or more selected from the group consisting of Kollidon CL, Kollidon CL-F, low-substituted hydroxypropylcellulose (L-HPC), croscarmellose, sodium starch glycolate, and polyvinylpyrrolidone (PVP).

4. An oral fast-disintegrating solid dosage form according to paragraph 2, wherein the lubricant comprises one or more selected from the group consisting of magnesium stearate, sodium stearyl fumarate, talc, and polyethylene glycol.

5. An oral fast-disintegrating solid dosage form according to claim 2, wherein the binder comprises one or more selected from the group consisting of hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), pregelatinized starch, Kollidone 30, and Kollidone VA 64.

6. An oral fast-disintegrating solid formulation according to paragraph 2, wherein the volatilization inhibitor comprises one or more selected from the group consisting of olive oil, soybean oil, canola oil, grapeseed oil, and sunflower oil.

7. An oral fast-disintegrating solid dosage form according to claim 1, wherein, with respect to 100 parts by weight of the solid dosage form, the aromatic component is 1 to 20 parts by weight.

8. An oral fast-disintegrating solid formulation according to claim 1, wherein the adsorbent comprises 1 to 20 parts by weight per 100 parts by weight of the solid formulation.

9. An oral fast-disintegrating solid dosage form according to claim 1, wherein the diluent is 60 to 95 parts by weight per 100 parts by weight of the solid dosage form.

10. An oral fast-disintegrating solid dosage form according to paragraph 2, wherein the disintegrating agent is 2 to 20 parts by weight per 100 parts by weight of the solid dosage form.

11. An oral fast-disintegrating solid dosage form according to paragraph 2, wherein the lubricant is 0.5 to 4 parts by weight per 100 parts by weight of the solid dosage form.

12. An oral fast-disintegrating solid dosage form according to paragraph 2, wherein the binder is 2 to 16 parts by weight per 100 parts by weight of the solid dosage form.

13. An oral fast-disintegrating solid dosage form according to paragraph 2, wherein, with respect to 100 parts by weight of the solid dosage form, the volatile inhibitor is 1 to 12 parts by weight.

14. In paragraph 1, the solid dosage form is an oral fast-disintegrating solid dosage form, which is a granule, tablet, capsule, or dry syrup.

15. A fragrance component comprising one or more selected from the group consisting of cinnamon scent, lemon scent, peppermint scent, rose scent and pine scent; An adsorbent comprising one or more selected from the group consisting of silicon dioxide, magnesium aluminosilicate, calcium silicate, and powdered crystalline glucose; A diluent comprising one or more selected from the group consisting of mannitol, sorbitol, xylitol, monohydrate lactose, microcrystalline cellulose, and corn starch; and An oral rapid disintegrating tablet comprising one or more disintegrating agents selected from the group consisting of kollidone CL, kollidone CL-F, low-substituted hydroxypropylcellulose (L-HPC), croscarmellose, sodium starch glycolate, and polyvinylpyrrolidone (PVP).

16. In paragraph 15, the oral disintegrating tablet further comprises one or more additives among a lubricant and a volatilization inhibitor.

17. In paragraph 15, the oral disintegrating tablet is an oral disintegrating tablet having a hardness of 3 to 7 kP.

18. In paragraph 15, the oral disintegrating tablet is an oral disintegrating tablet having an oral disintegration time of 30 seconds or less.

19. A fragrance component comprising one or more selected from the group consisting of cinnamon scent, lemon scent, peppermint scent, rose scent and pine scent; An adsorbent comprising one or more selected from the group consisting of silicon dioxide, magnesium aluminosilicate, calcium silicate, and powdered crystalline glucose; A diluent comprising one or more selected from the group consisting of mannitol, sorbitol, xylitol, monohydrate lactose, microcrystalline cellulose, and corn starch; and A granule preparation comprising a binder comprising one or more selected from the group consisting of hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), pregelatinized starch, Kollidone 30, and Kollidone VA 64.

20. The granular formulation according to claim 19, further comprising one or more additives among the granular formulation lubricant and volatilization inhibitor.

Images